FDA Approves Incyte’s Zynyz as First-Line and Second-Line Treatment for Advanced Anal Cancer

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.